Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy
This is a German, observational study in adult participants diagnosed with squamous cell carcinoma of the head and neck (SCCHN) progressing on or after platinum-based therapy, who start a new systemic therapy with nivolumab in 1st line (cohort 2) or ≥2nd line (cohort 1) for the first time, and are treated within the market authorization approval. Participants are to be enrolled into the study no earlier than the decision to initiate treatment with nivolumab and no later than the first dose of nivolumab treatment.
Head and Neck Cancer
Overall Survival, Up to 5 years
Overall Survival, Up to 5 years|Progression-Free Survival (PFS), Up to 5 years|Time to progression, Up to 5 years|Overall Response Rate (ORR), Up to 5 years|Best overall response rate (BORR), Up to 5 years|Best overall response (BOR), Up to 5 years|Tumor response (Investigator assessed), Up to 5 years|Time to response (TTR), Up to 5 years|Duration of response (DOR), Up to 5 years|Description of socio-demographic characteristics of participants, Up to 5 years|Description of clinical characteristics of participants, Up to 5 years|Description of management of participants with treatment-related adverse events (AEs), Up to 5 years|Description of incidence of AEs, Up to 5 years|Description of Severity of AEs, Up to 5 years|Description of management of AEs, Up to 5 years|Description of participant-reported outcomes (PROs) and health-related quality-of-life (QoL) of participants using the Functional Assessment of Cancer Therapy - Head & Neck (FACT-H&N) questionnaires, Up to 5 years|Description of participant-reported outcomes (PROs) and health-related quality-of-life (QoL) of participants using European Quality of Life-5 Dimensions (EQ-5D) questionnaires, Up to 5 years
This is a German, observational study in adult participants diagnosed with squamous cell carcinoma of the head and neck (SCCHN) progressing on or after platinum-based therapy, who start a new systemic therapy with nivolumab in 1st line (cohort 2) or ≥2nd line (cohort 1) for the first time, and are treated within the market authorization approval. Participants are to be enrolled into the study no earlier than the decision to initiate treatment with nivolumab and no later than the first dose of nivolumab treatment.